We are proud to announce the incorporation of Nioside® (Nintedanib) into our Pulmonology Division. This treatment is indicated for: Idiopathic pulmonary fibrosis (IPF) in adults. Other chr...
14
Aug
At Laboratorios ASPEN, we are pleased to introduce Vaxtor® (Ivacaftor), now part of our Oncology Division. Indicated for the treatment of cystic fibrosis, this new therapy broadens the options ava...
Laboratorios ASPEN incorporates Uveren® (Macitentan) into its Pulmonology Division, offering a new therapeutic alternative for patients with complex respiratory conditions. This treatment is indic...